Aqsens Health’s 2023 wrap-up
It’s time to wrap-up Aqsens Health’s 2023, a year of major scientific steps and large clinical trial kick-offs!
Here are our team’s highlights from the past year:
In 2023 we took an important step forward with the AQ Malaria test as our team at the Noguchi Memorial Institute for Medical Research collected over 2,500 malaria saliva samples, finished all PCR analyses and began the biosensor testing and optimization, both in Ghana and in Finland. Special thanks go to Finnpartnership who made this progress possible.
We deepened our partnership with Ghanaian partner Equity Health Insurance and its MedCare Plus clinic chain. They also visited our laboratory in Finland to further explore the capabilities of E-TRF and biosensors.
We kicked-off our BIOURICA clinical trial project in Nanjing, China, and started the collection of over 1,000 urine samples. The project's research collaboration partner OG Pharmaceuticals received funding from the Jiangsu Provincial Department of Science and Technology and Aqsens Health from Business Finland.
We also kicked-off the BIOSALIVA research study that focuses on lung cancer and tuberculosis detection from saliva with Shanghai Jiao Tong University. The study received funding from China’s Ministry of Science and Technology, as well as from Business Finland.
Lynx Financial assumed the role of Aqsens Health's financial advisor in China, guiding us toward an A-round in 2024 and facilitating our path to growth through strategic partnerships.
Sample collection for our metastatic cancer research project with Maria Sundvall began in TYKS and we received the first set of samples in August.
We took significant steps in the development and use of biosensors in detecting diseases from non-invasive samples. A new biosensor research collaboration began with Tambet Teesalu’s lab at the University of Tartu, and Professor Teesalu also became Aqsens’ Senior Scientific Advisor.
Aqsens was granted new European and US patents for the detection of prostate cancer and metastatic cancer, accompanied by the publication of a bifunctional biosensor paper authored by our Head of Laboratory Vilhelmiina Juusti, and Chief Scientific Officer Janne Kulpakko.
Sarah Laaru joined Aqsens Health’s team as a Business Development Advisor for Ghana and Africa, helping us navigate towards market entry in 2024.
We strengthened our research team as Elizabeth Cudjoe moved to Finland to start as a Senior Application Scientist focusing on biosensor development and malaria detection.
Aqsens, Peter Boström from TYKS and Auria biobank began a new research project to detect and classify bladder cancer from urine samples with phage-biosensors.
Our team at NMIMR completed beta testing for the AQ Lab web platform that we have been developing with Goodhum, and the platform is now ready to be deployed to the BIOSALIVA and BIOURICA projects in China, and later for 3rd party development.
